Novavax | NVAX - Cash And Equivalent


Novavax reported $191.46M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 136.02M 2.13M Jun/2026
Agenus USD 18.74M 16.26M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Geron USD 62.64M 6.25M Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
MannKind USD 52.93M 95K Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Moderna USD 1.72B 185M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Novavax USD 191.46M 36.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026